🔍 Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence JP/EN
Ethics · Regulation · Technology — Pharma Practice Notes
Independent chapter·10 topics + intermediate-gate template library·Published June 7, 2026

Material Requester (Manager)'s Responsibilities— Designing the intermediate gate before vendor deliverables get forwarded into internal material review

As a material requester (manager) inside a pharmaceutical company (the requesting party), simply receiving a vendor deliverable and forwarding it directly into internal material review is a common practice — but one that carries a problem of moral responsibility. Even when the vendor has executed QC and QA under the framework of Production Quality Management, the material requester (manager) still bears independent responsibility for confirming "conformance to the original SoW (Statement of Work)," "alignment with industry norms such as the JPMA Creation Guidelines," and "integrity with the company's internal Code of Practice, policies, and SOPs." This chapter systematizes that responsibility and designs an "intermediate gate" process that sits before internal material review submission — with AI prompts, check tables, gate-decision criteria, and record templates published incrementally.

01Why an Independent Chapter for the Material Requester (Manager) Is Needed

Most pharma materials directed at healthcare professionals and patients are produced through outside vendors (production companies, advertising agencies, medical content firms). The vendor executes QC and QA under Production Quality Management and hands off the deliverable with signed quality records. The material requester (manager) (the brand manager, marketing lead, MR education lead, or other internal "owner" of the material) receives it.

What tends to happen next is "trust the vendor's QC/QA, forward directly into internal material review." Efficient on the surface. The vendor is the specialist; the internal reviewer is the last line of defense. But this flow carries three problems of moral responsibility.

In short, the material requester (manager) is not "a forwarding mechanism" for vendor deliverables — the role carries the responsibility of functioning as an "intermediate gate." Before internal material review, the material requester (manager) must run an independent confirmation process. This is the chapter's central idea.

Mirror Relationship with the Production Quality Management Chapter

The Production Quality Management chapter addresses how quality is built in from the vendor side. This chapter (Material Requester (Manager)'s Responsibilities) is its mirror — designing the gate that sits between vendor delivery and internal material review, from the client side. Reading both together makes the division and complementarity of responsibility three-dimensional.

02The Four Pillars

Pillar 01

SoW Conformance Verification

Does the deliverable match the original SoW, concept brief, and requirements document? Detect out-of-scope additions, drift from the original purpose, and misalignment with the target patient population.

Pillar 02

Independent Re-Check of Vendor QC/QA

Independently re-examine the signed QC/QA records the vendor submits (using templates from the Production Quality Management chapter). Detect omissions, misjudgments, or overreactions on the vendor side.

Pillar 03

Alignment with Industry Norms (JPMA Creation Guidelines)

Re-confirm alignment with the JPMA Product Information Summary Creation Guidelines, Advertising Appropriateness Standards, HanteiG, and Pharmaceutical Act §§66–68 from the material requester (manager)'s independent perspective. Per-medium craft examined carefully.

Pillar 04

Integrity With Internal Code of Practice / Policies / SOPs

Judge integrity with the "spirit" of the company's Code of Practice, global / regional policies, product-specific SOPs, and the company's NG/OK case history. The material requester (manager) alone holds the cultural context required for these judgments.

03The 10-Topic Structure

Part 1 — The Moral-Responsibility Foundation
Part 2 — Designing the Intermediate Gate
Part 3 — Independent Re-Check of Vendor QC/QA
Part 4 — Industry Norm and Internal SOP Alignment
Part 5 — Gate Decision and Recording

04Appendices — Intermediate-Gate Template Library

This chapter publishes the following appendices on an ongoing basis, both embedded into topic articles and as standalone template pages.

Disclaimer

Use of This Chapter and Allocation of Responsibility

The documents, AI prompts, check tables, intermediate-gate decision forms, templates, and all other deliverables published in this chapter (collectively, "the Materials") are reference content for informational purposes. Pharmaceutical material requester (manager)s, related functions, and related parties are permitted to use, customize, and internalize the Materials at their own judgment and responsibility.

The "moral responsibility" discussed in this chapter is not a legal obligation. It is articulated as a normative expectation in industry and society. With respect to any and all consequences, damages, legal liability, regulatory actions, vendor disputes, third-party claims, or any other adverse outcomes arising from or related to the use of, reference to, or application of the Materials, Advertising Regulation in Japan (Promotional Material Review) and Artificial Intelligence, the authors of this site, and related parties bear no responsibility whatsoever.

The Materials do not guarantee they reflect the permanent latest version of regulations, statutes, industry norms, or internal SOPs. Pharmaceutical regulations (Pharmaceutical Act, Advertising Appropriateness Standards, HanteiG, JPMA Creation Guidelines, and others) and internal documents are periodically revised. Confirmation of the current version and final judgment rest with each entity using the Materials.

The Materials are not a substitute for legal counsel, legal advice, compliance services, or consulting services. For specific judgments required of the material requester (manager), consult internal compliance and legal teams, or external specialists (attorneys, pharmaceutical regulatory consultants, etc.).

← Back to Home